Relay Therapeutics (RLAY) EBIT (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of EBIT data on file, last reported at -$78.6 million in Q1 2026.

• On a quarterly basis, EBIT rose 7.4% year-over-year to -$78.6 million in Q1 2026; TTM through Mar 2026 was -$296.5 million, a 19.22% increase from a year earlier, with the FY2025 full-year figure at -$302.7 million, up 18.72% from the prior year.
• EBIT for Q1 2026 stood at -$78.6 million, down from -$60.6 million in the prior quarter.
• Over the last five years, EBIT for RLAY reached as high as -$60.6 million in Q4 2025 and fell as low as -$106.0 million in Q2 2023.
• Historically, EBIT has averaged -$83.9 million across 5 years, with a median of -$84.9 million in 2025.
• Across the five-year window, EBIT surged 59.8% in 2022 and slumped 61.31% in 2023, its largest moves.
• Year by year, EBIT stood at -$72.9 million in 2022, then fell by 26.55% to -$92.2 million in 2023, then rose by 7.83% to -$85.0 million in 2024, then rose by 28.65% to -$60.6 million in 2025, then retreated by 29.62% to -$78.6 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$78.6 million in Q1 2026, -$60.6 million in Q4 2025, and -$80.4 million in Q3 2025.